Clinical Trials
51 trialsA Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas
St. Jude Children's Research Hospital
AYAConnect
UNC Lineberger Comprehensive Cancer Center
ARC-12
Arcus Biosciences, Inc.
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
Incyte Corporation
Improved Early Diagnosis in Female Pelvic Cancer With OC Detect
Region Skane
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
Shattuck Labs, Inc.
Meteor 1
GlaxoSmithKline
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
National Cancer Institute (NCI)
ROOT
Taproot Health
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
National Cancer Institute (NCI)
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
National Institutes of Health Clinical Center (CC)
Evaluating the Effect of a Mobile Audio Companion (Elly) to Reduce Anxiety in Cancer Patients
Cedars-Sinai Medical Center
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
Sanguine Biosciences
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Celldex Therapeutics
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
Deciphera Pharmaceuticals, LLC
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
Rutgers, The State University of New Jersey
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
National Cancer Institute (NCI)
Follow-up Protocol for Patients With Cancer/AIDS/Skin Disease
National Institutes of Health Clinical Center (CC)
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Fate Therapeutics
A Study of PNT2258 in Patients With Advanced Solid Tumors
Sierra Oncology LLC - a GSK company
A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers
Ludwig Institute for Cancer Research
Mini-allo
Scripps Health
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
Incyte Corporation
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
Incyte Corporation
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Celgene
PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative
Memorial Sloan Kettering Cancer Center
A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab
Pfizer
Immunoablative Mini Transplant (Hematopoietic Peripheral Blood Stem Cell Transplant [HPBSC])
Ann & Robert H Lurie Children's Hospital of Chicago
18F-fluorodeoxyglucose (18F-FDG) Positron Emission Tomography in Oncology
British Columbia Cancer Agency
LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab
Lytix Biopharma AS
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
Celldex Therapeutics
NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma
Celgene
Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants
Wake Forest University Health Sciences
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Novartis
Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children
University of Washington
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
Rutgers, The State University of New Jersey
IFNa
The Cleveland Clinic
An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155
Astellas Pharma Inc
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Rapamycin With Grapefruit Juice for Advanced Malignancies
University of Chicago
Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies
Altor BioScience
Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer
Memorial Sloan Kettering Cancer Center
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
National Cancer Institute (NCI)
BCX-1777 in Treating Patients With Refractory Cancer
National Cancer Institute (NCI)
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
Novartis
Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas
National Institutes of Health Clinical Center (CC)
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
National Institutes of Health Clinical Center (CC)
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
Case Comprehensive Cancer Center
PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)
Pfizer
A Phase I Study of Oral COL-3 (NSC-683551), a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer
National Institutes of Health Clinical Center (CC)